279 related articles for article (PubMed ID: 18204355)
1. Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function.
Ravindran LN; Eisfeld BS; Kennedy SH
J Clin Psychopharmacol; 2008 Feb; 28(1):107-8. PubMed ID: 18204355
[No Abstract] [Full Text] [Related]
2. Mirtazapine for treatment of nausea induced by selective serotonin reuptake inhibitors.
Caldis EV; Gair RD
Can J Psychiatry; 2004 Oct; 49(10):707. PubMed ID: 15560319
[No Abstract] [Full Text] [Related]
3. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
Lee SI; Keltner NL
Perspect Psychiatr Care; 2006 May; 42(2):144-8. PubMed ID: 16677140
[No Abstract] [Full Text] [Related]
4. Duloxetine-induced cutaneous adverse reaction.
Oulis P; Masdrakis VG; Karakatsanis NA; Karapoulios E; Kouzoupis AV; Soldatos CR
J Clin Psychopharmacol; 2008 Feb; 28(1):104-5. PubMed ID: 18204353
[No Abstract] [Full Text] [Related]
5. Relief of SSRI-induced sexual dysfunction with mirtazapine treatment.
Farah A
J Clin Psychiatry; 1999 Apr; 60(4):260-1. PubMed ID: 10221289
[No Abstract] [Full Text] [Related]
6. Manic switching in patients receiving duloxetine.
de Dios C; Ezquiaga E
Am J Psychiatry; 2007 Jul; 164(7):1121. PubMed ID: 17606669
[No Abstract] [Full Text] [Related]
7. Digging for data on harms in duloxetine trials.
Doshi P; Zito J; dosReis S
BMJ; 2014 Jun; 348():g3578. PubMed ID: 24904123
[No Abstract] [Full Text] [Related]
8. Burning paresthesia related to duloxetine therapy.
Woo YS; Bahk WM
J Clin Psychopharmacol; 2014 Jun; 34(3):392-4. PubMed ID: 24633002
[No Abstract] [Full Text] [Related]
9. Successful duloxetine use to prevent venlafaxine withdrawal symptoms.
Hsiao MC; Liu CY
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):576. PubMed ID: 17889418
[No Abstract] [Full Text] [Related]
10. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors.
Ozmenler NK; Karlidere T; Bozkurt A; Yetkin S; Doruk A; Sutcigil L; Cansever A; Uzun O; Ozgen F; Ozsahin A
Hum Psychopharmacol; 2008 Jun; 23(4):321-6. PubMed ID: 18278806
[TBL] [Abstract][Full Text] [Related]
11. Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study.
Dueñas H; Lee A; Brnabic AJ; Chung KF; Lai CH; Badr MG; Uy-Ponio T; Ruiz JR; Varrey P; Jian H; Dossenbach M
Int J Psychiatry Clin Pract; 2011 Jun; 15(2):80-90. PubMed ID: 22121855
[TBL] [Abstract][Full Text] [Related]
12. Re: Hemorrhages during escitalopram-venlafaxine-mirtazapine combination treatment of depression.
Al-Adwani A
Can J Psychiatry; 2005 Nov; 50(13):877; author reply 877-8. PubMed ID: 16483124
[No Abstract] [Full Text] [Related]
13. Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period.
Dueñas H; Brnabic AJ; Lee A; Montejo AL; Prakash S; Casimiro-Querubin ML; Khaled M; Dossenbach M; Raskin J
Int J Psychiatry Clin Pract; 2011 Nov; 15(4):242-54. PubMed ID: 22121997
[TBL] [Abstract][Full Text] [Related]
14. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine related hypersexuality: a case report.
Lai CH
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):414-5. PubMed ID: 19945494
[No Abstract] [Full Text] [Related]
16. Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants.
Ashton AK; Longdon MC
Am J Psychiatry; 2007 Jul; 164(7):1121-2. PubMed ID: 17606668
[No Abstract] [Full Text] [Related]
17. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.
Delgado PL; Brannan SK; Mallinckrodt CH; Tran PV; McNamara RK; Wang F; Watkin JG; Detke MJ
J Clin Psychiatry; 2005 Jun; 66(6):686-92. PubMed ID: 15960560
[TBL] [Abstract][Full Text] [Related]
18. Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study.
Seguí J; López-Muñoz F; Alamo C; Camarasa X; García-García P; Pardo A
J Psychopharmacol; 2010 Aug; 24(8):1201-7. PubMed ID: 19282423
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder.
Brecht S; Kajdasz D; Ball S; Thase ME
Int Clin Psychopharmacol; 2008 Nov; 23(6):317-24. PubMed ID: 18854719
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine.
Pitchot W; Scantamburlo G; Ansseau M
Psychiatr Danub; 2010 Nov; 22 Suppl 1():S106-7. PubMed ID: 21057413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
